News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Gilead Sciences, Inc. Profit Rises a Higher-than-Expected 21 Percent
April 21, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters - Gilead Sciences Inc (GILD.O) said on Tuesday first-quarter profit rose 21 percent, topping analysts' expectations, on increased sales of its drugs to treat the virus that causes AIDS.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Gilead Sciences, Inc.
MORE ON THIS TOPIC
Gene editing
Startup Aurora Seeks To Replicate Baby KJ Success With $16M in Seed Money
January 12, 2026
·
2 min read
·
Tristan Manalac
IPO
Veradermics, Eikon Eye Public Market Debut as IPO Tap Opens
January 12, 2026
·
2 min read
·
Tristan Manalac
Earnings
Insmed Jumps on ‘Blowout’ Sales Beat for Bronchiectasis Drug Brinsupri
January 9, 2026
·
1 min read
·
Dan Samorodnitsky
Lung cancer
Roche Spends $570M on Another ADC Agreement With China’s MediLink
January 9, 2026
·
1 min read
·
Tristan Manalac
